PRME Prime Medicine, Inc.

Overview and Growth

In fiscal 2025, Prime Medicine, Inc. recorded $4.63M of revenue, net loss of $201.14M, and an operating cash outflow of $162.56M. The $4.63M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. Revenue was 55.3% above fiscal 2024 revenue of $2.98M, marking a year-over-year increase. The company reported diluted EPS of -$1.35, adding a shareholder-level measure to the absolute income figures considered below. A diluted share base of 148.76M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Compared with 118.60M diluted shares in fiscal 2024, the current 148.76M base was 25.4% higher. Total assets stood at $342.73M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Revenue equaled 0.01x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

Operations produced a $208.35M operating loss before non-operating and tax effects. After all below-operating-line items, the company recorded a net loss of $201.14M for the fiscal year. EBITDA was negative $201.03M, showing a deficit before interest, taxes, depreciation, and amortization. The company recognized $0.00 of income tax for the period, completing the transition from pretax income to net income. The loss-to-equity relationship was 166.4%, placing the bottom-line deficit against shareholder capital. Relative to total assets, the net loss represented 58.7%. Compared with a $195.88M net loss in fiscal 2024, the current loss increased to $201.14M.

Liquidity and Capital Structure

At period end, the $342.73M asset base was financed through $221.87M of liabilities and $120.87M of equity. The near-term balance sheet paired $181.29M of current assets with $37.45M of current liabilities at the reporting date. Current assets covered current liabilities by 4.84x, leaving a positive buffer for near-term obligations. Cash and equivalents totaled $63.03M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 168.3%, excluding receivables and other current assets. Equity equaled 35.3% of assets, showing the shareholder-capital layer within the company’s balance sheet. Liabilities represented 64.7% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 18.4% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $297.51M in fiscal 2024, the current asset base moved 15.2% and finished higher. Reported equity changed 21.1% from $153.15M in fiscal 2024, placing the current capital base lower year over year. The reported cash balance changed 65.5% from $182.48M in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $162.56M, showing that operations absorbed cash during the period. The company spent $4.53M on capital expenditures while operations also absorbed cash, so both ongoing activity and investment drew on liquidity during the period. Negative free cash flow was $167.09M, leaving a cash deficit after capital spending and reducing financial flexibility. Relative to total assets, the post-investment cash deficit measured 48.8%. The operating cash outflow widened to $162.56M from $122.86M in fiscal 2024.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Sep 24, 2026.